1030613-24-1

Basic information

• Product Name: Ethyl 2-(5-(5-(4-(2-broMo-5-fluorophenoxy)piperidin-1-yl)-1,3,4-thiadiazol-2-yl)-1H-tetrazol-1-yl)acetate
• Synonyms: Ethyl 2-(5-(5-(4-(2-broMo-5-fluorophenoxy)piperidin-1-yl)-1,3,4-thiadiazol-2-yl)-1H-tetrazol-1-yl)acetate;ethyl (5-{5-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-1,3,4-thiadiazol-2-yl}-1H-tetrazol-1-yl)acetate
• CAS NO: 1030613-24-1
• Molecular Formula: C₁₈H₁₉BrFN₇O₃S
• Molecular Weight: 512.3559632
• Mol File: 1030613-24-1.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Ethyl 2-(5-(5-(4-(2-broMo-5-fluorophenoxy)piperidin-1-yl)-1,3,4-thiadiazol-2-yl)-1H-tetrazol-1-yl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 2-(5-(5-(4-(2-broMo-5-fluorophenoxy)piperidin-1-yl)-1,3,4-thiadiazol-2-yl)-1H-tetrazol-1-yl)acetate(1030613-24-1)
• EPA Substance Registry System: Ethyl 2-(5-(5-(4-(2-broMo-5-fluorophenoxy)piperidin-1-yl)-1,3,4-thiadiazol-2-yl)-1H-tetrazol-1-yl)acetate(1030613-24-1)

Safety Data

• Hazardous Substances Data: 1030613-24-1(Hazardous Substances Data)

Usage

Uses

Ethyl 2-(5-(5-(4-(2-Bromo-5-fluorophenoxy)piperidin-1-yl)-1,3,4-thiadiazol-2-yl)-1H-tetrazol-1-yl)acetate is an intermediate in the synthesis of azacycloalkane derivatives as inhibitors of stearoyl-CoA desaturase.

Upstream product

• 147460-41-1 2-bromo-5-fluorophenol 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 1030613-20-7 4-(2-bromo-5-fluorophenoxy)-1-[5-(2H-tetrazol-5-yl)-1,3,4-thiadiazol-2-yl]piperidine 
• 105-36-2 ethyl bromoacetate 
• 1020658-57-4 5-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-1,3,4-thiadiazole-2-carbonitrile 
• 916971-27-2 4-(2-bromo-5-fluorophenoxy)piperidine 

Relevant articles and documents

Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia

The potential use of SCD inhibitors for the chronic treatment of diabetes and dyslipidemia has been limited by preclinical adverse events associated with inhibition of SCD in skin and eye tissues. To establish a therapeutic window, we embarked on designing liver-targeted SCD inhibitors by utilizing molecular recognition by liver-specific organic anion transporting polypeptides (OATPs). In doing so, we set out to target the SCD inhibitor to the organ believed to be responsible for the therapeutic efficacy (liver) while minimizing its exposure in the tissues associated with mechanism-based SCD depletion of essential lubricating lipids (skin and eye). These efforts led to the discovery of MK-8245 (7), a potent, liver-targeted SCD inhibitor with preclinical antidiabetic and antidyslipidemic efficacy with a significantly improved therapeutic window.